OTCPK:AQQR.F

Stock Analysis Report

Aquarius Surgical Technologies

Executive Summary

Aquarius Surgical Technologies Inc., through its subsidiary, Surgical Lasers Inc., engages in the development, sale, distribution, marketing, and exploitation of laser-driven technologies in for use in surgical environments, principally in the field of urology in North America.


Snowflake Analysis

Weak fundamentals or lack of information.

Share Price & News

How has Aquarius Surgical Technologies's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: AQQR.F has not had significant price volatility in the past 3 months.


Market Performance


7 Day Return

0%

AQQR.F

-1.3%

US Medical Equipment

-1.1%

US Market


1 Year Return

n/a

AQQR.F

19.4%

US Medical Equipment

17.8%

US Market

Return vs Industry: Insufficient data to determine how AQQR.F performed against the US Medical Equipment industry.

Return vs Market: Insufficient data to determine how AQQR.F performed against the US Market.


Shareholder returns

AQQR.FIndustryMarket
7 Day0%-1.3%-1.1%
30 Day-4.9%0.02%1.5%
90 Dayn/a5.5%6.6%
1 Yearn/a20.3%19.4%20.2%17.8%
3 Yearn/a79.2%74.2%47.5%38.1%
5 Yearn/a114.6%92.0%71.2%52.4%

Price Volatility Vs. Market

How volatile is Aquarius Surgical Technologies's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Aquarius Surgical Technologies undervalued compared to its fair value and its price relative to the market?


In this section, we usually try to help investors determine whether Aquarius Surgical Technologies is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Aquarius Surgical Technologies has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.


Next Steps

  • Take a look at our analysis of AQQR.F’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don’t know where to start, we recommend reading through Aquarius Surgical Technologies regulatory filings here.
  • Explore potentially undervalued companies in the Healthcare industry.

Future Growth

How is Aquarius Surgical Technologies forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

13.6%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Aquarius Surgical Technologies has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

  • Take a look at our analysis of AQQR.F’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on the OTC Markets Website. If you are looking for more of a qualitative research into the company, you can access Aquarius Surgical Technologies's filings and announcements here.
  • Explore growth companies in the Healthcare industry.

Past Performance

How has Aquarius Surgical Technologies performed over the past 5 years?

-58.3%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: AQQR.F is currently unprofitable.

Growing Profit Margin: AQQR.F is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: AQQR.F is unprofitable, and losses have increased over the past 5 years at a rate of -58.3% per year.

Accelerating Growth: Unable to compare AQQR.F's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: AQQR.F is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (1.7%).


Return on Equity

High ROE: AQQR.F's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is Aquarius Surgical Technologies's financial position?


Financial Position Analysis

Short Term Liabilities: AQQR.F has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.

Long Term Liabilities: AQQR.F has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.


Debt to Equity History and Analysis

Debt Level: AQQR.F has negative shareholder equity, which is a more serious situation than a high debt level.

Reducing Debt: AQQR.F's has negative shareholder equity, so we do not need to check if its debt has reduced over time.


Balance Sheet

Inventory Level: AQQR.F has a high level of physical assets or inventory.

Debt Coverage by Assets: AQQR.F has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: AQQR.F has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: AQQR.F has less than a year of cash runway if free cash flow continues to reduce at historical rates of -45.7% each year


Next Steps

Dividend

What is Aquarius Surgical Technologies's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.4%markettop25%3.7%industryaverage1.2%forecastin3Yearsn/a

Current dividend yield vs market & industry

Notable Dividend: Unable to evaluate AQQR.F's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate AQQR.F's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if AQQR.F's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if AQQR.F's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of AQQR.F's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.9yrs

Average management tenure


CEO

N. Van Nest (83yo)

2.9yrs

Tenure

CA$72,000

Compensation

Mr. N. Gary Van Nest, B.Comm., M.B.A. serves as the President of Sinalta Investments Ltd. Mr. Van Nest has over 38 years of extensive experience in the brokerage, merchant banking and investment management ...


CEO Compensation Analysis

Compensation vs Market: N.'s total compensation ($USD54.49K) is below average for companies of similar size in the US market ($USD521.92K).

Compensation vs Earnings: N.'s compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
N. Van Nest
CEO & Vice Chairman2.9yrsCA$72.00k0.29% CA$18.5k
Gordon Willox
President2.9yrsCA$228.00k20.14% CA$1.3m
Lorne MacFarlane
Chief Financial Officer10.3yrsno datano data
Stanley Swierzewski
Chief of Urology & Independent Director2.9yrsno datano data
Christopher Freeman
Secretary0yrsno datano data

2.9yrs

Average Tenure

Experienced Management: AQQR.F's management team is considered experienced (2.9 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
N. Van Nest
CEO & Vice Chairman2.9yrsCA$72.00k0.29% CA$18.5k
Gordon Willox
President2.9yrsCA$228.00k20.14% CA$1.3m
Stanley Swierzewski
Chief of Urology & Independent Director2.9yrsno datano data
David Hennigar
Independent Chairman of the Board0yrsno data2.8% CA$176.3k
Robert Francis
Independent Director2.9yrsno datano data

2.9yrs

Average Tenure

Experienced Board: AQQR.F's board of directors are not considered experienced ( 2.9 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 6.7%.


Top Shareholders

Company Information

Aquarius Surgical Technologies Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Aquarius Surgical Technologies Inc.
  • Ticker: AQQR.F
  • Exchange: OTCPK
  • Founded: 1986
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: CA$8.333m
  • Listing Market Cap: CA$6.306m
  • Shares outstanding: 22.83m
  • Website: https://www.surgicallasersinc.com

Location

  • Aquarius Surgical Technologies Inc.
  • 89 Scollard Street
  • Toronto
  • Ontario
  • M5R 1G4
  • Canada

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
AQQR.FOTCPK (Pink Sheets LLC)YesCommon SharesUSUSDJun 2017
ASTICNSX (Canadian National Stock Exchange)YesCommon SharesCACADJun 2017

Biography

Aquarius Surgical Technologies Inc., through its subsidiary, Surgical Lasers Inc., engages in the development, sale, distribution, marketing, and exploitation of laser-driven technologies in for use in surgical environments, principally in the field of urology in North America. It provides multi-diode laser systems and related fibre-optic delivery devices for minimally invasive treatment of benign prostatic hyperplasia. The company also offers solutions comprising clinical education, service, support, and maintenance, as well as consumables. The company was formerly known as Aquarius Coatings Inc. Aquarius Surgical Technologies Inc. was incorporated in 1986 and is based in Toronto, Canada. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/02/24 02:45
End of Day Share Price2020/02/11 00:00
Earnings2019/09/30
Annual Earnings2019/03/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.